File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.ijgo.2009.11.007
- Scopus: eid_2-s2.0-76049110718
- WOS: WOS:000275615000030
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Community-based distribution of misoprostol for treatment or prevention of postpartum hemorrhage: Cost-effectiveness, mortality, and morbidity reduction analysis
Title | Community-based distribution of misoprostol for treatment or prevention of postpartum hemorrhage: Cost-effectiveness, mortality, and morbidity reduction analysis |
---|---|
Authors | |
Keywords | Anemia Cost-effectiveness Maternal mortality Misoprostol Postpartum hemorrhage |
Issue Date | 2010 |
Citation | International Journal of Gynecology and Obstetrics, 2010, v. 108, n. 3, p. 289-294 How to Cite? |
Abstract | Objective: To compare the cost-effectiveness of community-based distribution of misoprostol for prevention with misoprostol for treatment of postpartum hemorrhage (PPH). Methods: A Monte Carlo simulation depicted mortality and anemia-related morbidity attributable to PPH among 3 scenarios of 10 000 women delivering at home in rural India: (1) standard management; (2) standard management plus 800 μg of sublingual misoprostol for PPH treatment; and (3) standard management plus 600 μg of prophylactic oral misoprostol. The model included costs of drugs, birth attendant training, and transport for women who did not respond to misoprostol. Results: Misoprostol lowered mortality by 70% and 81% in scenarios 2 and 3, respectively. Scenarios 2 and 3 raise costs by 6% and 35%, respectively. Incremental cost per disability-adjusted life year (DALY) saved is estimated at $6 and $170, respectively. Conclusion: Both interventions were more effective at decreasing mortality and anemia than standard management. The most efficient scale-up plan would focus initially on increasing coverage with the treatment strategy ($6 per DALY). © 2009 International Federation of Gynecology and Obstetrics. |
Persistent Identifier | http://hdl.handle.net/10722/326797 |
ISSN | 2023 Impact Factor: 2.6 2023 SCImago Journal Rankings: 0.951 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sutherland, Tori | - |
dc.contributor.author | Meyer, Carinne | - |
dc.contributor.author | Bishai, David M. | - |
dc.contributor.author | Geller, Stacie | - |
dc.contributor.author | Miller, Suellen | - |
dc.date.accessioned | 2023-03-31T05:26:34Z | - |
dc.date.available | 2023-03-31T05:26:34Z | - |
dc.date.issued | 2010 | - |
dc.identifier.citation | International Journal of Gynecology and Obstetrics, 2010, v. 108, n. 3, p. 289-294 | - |
dc.identifier.issn | 0020-7292 | - |
dc.identifier.uri | http://hdl.handle.net/10722/326797 | - |
dc.description.abstract | Objective: To compare the cost-effectiveness of community-based distribution of misoprostol for prevention with misoprostol for treatment of postpartum hemorrhage (PPH). Methods: A Monte Carlo simulation depicted mortality and anemia-related morbidity attributable to PPH among 3 scenarios of 10 000 women delivering at home in rural India: (1) standard management; (2) standard management plus 800 μg of sublingual misoprostol for PPH treatment; and (3) standard management plus 600 μg of prophylactic oral misoprostol. The model included costs of drugs, birth attendant training, and transport for women who did not respond to misoprostol. Results: Misoprostol lowered mortality by 70% and 81% in scenarios 2 and 3, respectively. Scenarios 2 and 3 raise costs by 6% and 35%, respectively. Incremental cost per disability-adjusted life year (DALY) saved is estimated at $6 and $170, respectively. Conclusion: Both interventions were more effective at decreasing mortality and anemia than standard management. The most efficient scale-up plan would focus initially on increasing coverage with the treatment strategy ($6 per DALY). © 2009 International Federation of Gynecology and Obstetrics. | - |
dc.language | eng | - |
dc.relation.ispartof | International Journal of Gynecology and Obstetrics | - |
dc.subject | Anemia | - |
dc.subject | Cost-effectiveness | - |
dc.subject | Maternal mortality | - |
dc.subject | Misoprostol | - |
dc.subject | Postpartum hemorrhage | - |
dc.title | Community-based distribution of misoprostol for treatment or prevention of postpartum hemorrhage: Cost-effectiveness, mortality, and morbidity reduction analysis | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.ijgo.2009.11.007 | - |
dc.identifier.scopus | eid_2-s2.0-76049110718 | - |
dc.identifier.volume | 108 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 289 | - |
dc.identifier.epage | 294 | - |
dc.identifier.isi | WOS:000275615000030 | - |